Telix Pharmaceuticals Limited
TLPPF
$16.05
-$0.1419-0.88%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 32.91M | 32.67M | 32.28M | 20.69M | 3.06M |
| Total Depreciation and Amortization | 5.29M | 5.04M | 4.75M | 4.51M | 4.47M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.63M | 25.27M | 17.55M | 14.45M | 30.19M |
| Change in Net Operating Assets | -42.47M | -32.45M | -21.89M | -21.89M | -21.89M |
| Cash from Operations | 28.36M | 30.53M | 32.69M | 17.76M | 15.84M |
| Capital Expenditure | -19.01M | -13.33M | -7.44M | -6.84M | -6.39M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -20.37M | -17.90M | -15.36M | 1.80K | 1.80K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -49.85M | -36.26M | -22.16M | -14.62M | -10.33M |
| Cash from Investing | -89.23M | -67.49M | -44.96M | -21.46M | -16.72M |
| Total Debt Issued | 655.94M | 330.96M | 5.97M | 5.49M | 5.76M |
| Total Debt Repaid | -3.13M | -2.91M | -2.69M | -1.91M | -2.22M |
| Issuance of Common Stock | 999.00K | 2.68M | 4.36M | 6.06M | 6.65M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -14.88M | -7.44M | 0.00 | -2.83M | -- |
| Cash from Financing | 422.22M | 216.54M | 5.00M | 4.49M | 6.75M |
| Foreign Exchange rate Adjustments | 26.65M | 12.92M | -1.18M | 245.90K | -1.05M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 387.99M | 192.50M | -8.45M | 1.04M | 4.82M |
